Actively Recruiting
Immunological Aspects of Thrombotic Thrombocytopenic Purpura (TTP): Characterisation of B and T Lymphocytes Specific for the ADAMTS13 Autoantigen and Therapeutic Implications
Led by University Hospital, Rouen · Updated on 2026-05-04
44
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to better understand thrombotic thrombocytopenic purpura (TTP), a serious condition marked by low platelets, anemia, and organ problems. The study focuses on identifying specific immune cells called ADAMTS13-specific memory B lymphocytes and autoreactive T lymphocytes, especially follicular helper T cells, during different phases of TTP. Researchers want to clarify how these cells contribute to the disease's start, changes after treatment, and their role in cases resistant to standard therapies or relapses. The goal is to find early signals that predict relapse and help tailor treatments for lasting remission. The study observes patients diagnosed with TTP at various stages including acute phase, remission, and relapse. Participants will be grouped based on their disease status and ADAMTS13 activity levels. The research involves consultations or hospital visits at diagnosis, follow-up appointments, before any preemptive treatment, and at relapse if it occurs. No experimental drugs or treatments are given as this is an observational study. Participants will be evaluated at enrollment, and again at 3, 6, and 12 months. During these visits, blood samples will be taken to identify and measure the presence and characteristics of autoreactive B and T lymphocytes related to ADAMTS13. Researchers will monitor changes in these immune cells over time to understand their role in disease progression and response to treatment. This study provides important insights into immune factors affecting TTP, with participation lasting up to one year after enrollment.
CONDITIONS
Brief Title
Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years
- Diagnosis of thrombotic thrombocytopenic purpura (TTP) at any stage (acute phase, remission, or relapse)
- Receiving internal medicine care at Rouen University Hospital
- Has read and understood the information letter
- Membership in a social security scheme
You will not qualify if you...
- Individuals deprived of liberty by administrative or judicial decision
- Individuals under court protection, guardianship, or similar legal supervision
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants are monitored through scheduled visits to assess circulating autoreactive B and T lymphocytes and their phenotypic characteristics.
Visits at enrollment, Month 3, Month 6, and Month 12
Trial Site Locations
Total: 1 location
1
University Rouen Hospital,
Rouen, France, 76031
Actively Recruiting
Research Team
D
David DM MALLET, Director
V
Vincent VF FERRANTI, ARC
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here